C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 235/06 (2006.01) A61K 31/4184 (2006.01) C07D 235/14 (2006.01) C07D 235/16 (2006.01)
Patent
CA 2440037
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, .beta..beta.-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis. An example of a compound embodying the invention is (see above formula)
La présente invention concerne certains composés, leur procédé d'élaboration, des compositions pharmaceutiques à vase de ces composés, et leur utilisation pour le traitement de trouvles humains ou animaux. Les composés de l'invention conviennent comme modulateur de l'interaction entre le récepteur de produits avancés à terminaison glyquée (ou "RAGE" pour "Receptor for Advanced Glycated End products") et ses ligands, et notamment les produits avancés à terminaison glyquée (AGE), les S100/calgranuline/EN-RAGE, ss-amyloïde et amphotérine. Ces composés conviennent également pour la gestion, le traitement, le contrôle de maladies imputables aux RAGE et affectant les humains, ou comme traitement d'appoint. Ces maladies ou états pathologiques sont essentiellement l'inflammation aiguë ou chronique, le développement de complications diabétiques tardives telles que l'accroissement de la perméabilité vasculaire, la néphropathie, l'athérosclérose et la rétinopathie, le dveloppement de la maladie d'Alzheimer, les troubles de l'érection, l'invasion tumorale et la métastase.
Gopalaswamy Ramesh
Mjalli Adnan M. M.
Moffat & Co.
Transtech Pharma Inc.
LandOfFree
Benzimidazole derivatives for modulating the rage receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazole derivatives for modulating the rage receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole derivatives for modulating the rage receptor will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1497154